Trump Orders Drug Advertising Crackdown as RFK Jr. Wants 'Radical Transparency' From Pharmaceutical Companies

The Trump administration is cracking down on direct-to-consumer pharmaceutical advertising. The U.S. Department of Health and Human Services and the Food and Drug Administration will move to eliminate an "adequate provision" loophole that allows drug companies to disclose an abbreviated version of a product's side affects in their ads. The rule, established in 1997, allowed companies to give a "major-risk statement" before pointing viewers to a website, toll-free number or print insert for more complete information. The FDA will also step up enforcement of DTC violations, with plans . . .